News

Optigenex has entered into a long term exclusive license agreement with Promethean for distribution and marketing of branded cosmeceutical and dietary supplement products containing AC-11. AC-11 is a

NeoPharm has filed an investigational new drug application (IND) with the FDA for IL13-PE38QQR (IL13-PE), for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company said that the

Adventrx Pharmaceuticals (Adventrx) has submitted a new drug application (NDA) to the FDA for its product candidate ANX-530 (vinorelbine injectable emulsion). The company is seeking approval of ANX-530

Dr. Reddy’s Laboratories and Rheoscience, a subsidiary of Nordic Bioscience, have reported the headline results from the first phase III study for their investigational agent, Balaglitazone. Reportedly, the

Evolva has signed an agreement with Roche, to create compounds with activity on targets in oncology and anti-infectives using Evolva’s technology platform. Roche is expected to pay Evolva

Advaxis has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980, titled ‘Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens,’ has

The FDA has accepted for review and granted priority review designation for the InterMune’s New Drug Application (NDA) for Pirfenidone, for the treatment of patients with idiopathic pulmonary

Elusys Therapeutics (Elusys) has signed a contract totaling $143m with the US Government to complete the final development, commercial manufacturing and licensure of Anthim, a late stage anthrax

Novartis intends to gain full ownership of Alcon by completing the April 2008 agreement with Nestle to acquire a 77% majority stake in eye care and subsequently entering